Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease

A Carroccio, L Giannitrapani, M Soresi, T Not, G Iacono, C Di Rosa, E Panfili, A Notarbartolo, G Montalto

Abstract

Background—It has been suggested that serological screening for coeliac disease (CD) should be performed in patients with chronic unexplained hypertransaminasaemia.

Aims—To evaluate the specificity for CD diagnosis of serum IgA antitissue transglutaminase (tTG) determination in consecutive patients with chronic hypertransaminasaemia using the most widely utilised ELISA based on tTG from guinea pig as the antigen.

Patients and methods—We studied 98 patients with chronic hypertransaminasaemia, evaluated for the first time in a hepatology clinic. Serum anti-tTG and antiendomysial (EmA) assays were performed. Patients positive for EmA and/or anti-tTG were proposed for intestinal biopsy. Finally, all sera were reassayed for anti-tTG using an ELISA based on human recombinant tTG as the antigen.

Results—A total of 94/98 hypertransaminasaemic patients were positive for hepatitis virus markers, with 82/98 (83%) positive for anti-hepatitis C virus. Liver histology showed that most patients had mild or moderate chronic hepatitis while severe fibrosis or overt liver cirrhosis was found in 20/98. CD screening showed that 15/98 (16%) hypertransaminasaemic subjects had anti-tTG values in the same range as CD patients; however, IgA EmA were positive in only 2/98 (2%). Distal duodenal biopsy, performed in nine patients, showed subtotal villous atrophy in the two EmA+/anti-tTG+ patients but was normal in 7/7 EmA−/anti-tTG+ subjects. The presence of anti-tTG+ values in EmA− patients was unrelated to particular gastrointestinal symptoms, other associated diseases, severity of liver histology, or distribution of viral hepatitis markers. There was a significantly higher frequency of positive serum autoantibodies (antineuclear, antimitochondrial, antismooth muscle, and anti-liver-kidney microsomal antibodies) in anti-tTG+/EmA− patients than in the other subjects (9/13 vs 10/83; p<0.003). Also, a correlation was found between serum gamma globulin and anti-tTG values (p<0.01). When sera were tested with the ELISA based on human tTG as the antigen, no false positive results were observed: only the two EmA+ patients with atrophy of the intestinal mucosa were positive for anti-tTG while all others were negative, including those false positive in the ELISA based on guinea pig tTG as the antigen.

Conclusions—In patients with elevated transaminases and chronic liver disease there was a high frequency of false positive anti-tTG results using the ELISA based on tTG from guinea pig as the antigen. Indeed, the presence of anti-tTG did not correlate with the presence of EmA or CD. These false positives depend on the presence of hepatic proteins in the commercial tTG obtained from guinea pig liver and disappear when human tTG is used as the antigen in the ELISA system. We suggest that the commonly used tTG ELISA based on guinea pig antigen should not be used as a screening tool for CD in patients with chronic liver disease.

Hepatic damage is a frequent finding in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in patients with coeliac disease (CD) on a gluten containing diet; in fact, hypertransaminasaemia has been reported in 10–54% of patients at CD diagnosis. As a consequence, it has been suggested that serological screening for CD should be performed in patients with chronic unexplained hypertransaminasaemia. In this respect, a previous study revealed that the serum antiendomysial antibody (EmA) assay is the optimum test for predicting CD in patients with chronic liver disease but this indirect immunofluorescence test is not easy to apply in large scale screening. However, tissue transglutaminase (tTG) has recently been identified as the main (or sole) autoantigen recognised by EmA in CD patients and this has permitted the use of an ELISA test, based on commercial guinea pig tissue transglutaminase, to detect the presence of anti-tTG autoantibodies in
Anti-tTG autoantibodies in chronic liver diseases

AntitTG autoantibodies in chronic liver diseases diagnosis,7–11 and when positive results have very rare false positive results for CD. Previous studies on the clinical utility of serum, specific for the diagnosis of CD.7–11 However, as in the case of patients with chronic liver disease (primary biliary cirrhosis), the occurrence of false positive anti-tTG antibody results has been found.12

In the present study, we evaluated serum anti-tTG and EmA in consecutive patients with chronic hypertransaminasemia due to various causes.

Patients and methods
The study included 98 consecutive subjects (66 males; age range 18–64 years, median 36) with chronic hypertransaminasemia (serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels >40 IU/l for more than two months) who attended the outpatient clinic for liver disease at the Internal Medicine Division of the University Hospital of Palermo for the first time between September 1998 and May 1999. Patients previously hospitalised in our division or examined in our outpatient clinics for liver or gastrointestinal diseases were excluded; we also excluded subjects with known CD and those who in the past had undergone complete serological evaluation for CD diagnosis.

In all patients, alcohol intake, use of drugs, and exposure to potential hepatic toxins were investigated. Laboratory investigations included routine liver and kidney function tests. Immunoglobulin levels were evaluated to exclude IgA deficiency. Furthermore, all subjects underwent serological screening for viral hepatitis B and C (HCV); anti-HCV immuno-reactivity was confirmed by a third generation immunoblot assay (RIBA 3; Chiron Corporation, Emeryville, California, USA, and Ortho Diagnostic Systems). Sera were also tested for hepatitis B surface antigen using a commercial ELISA (Abbott Diagnostic, North Chicago, Illinois, USA). In all subjects the presence of antinuclear (ANA), antimitochondrial (AMA), antismooth muscle (ASMA), and anti-liver-kidney microsomal (anti-LKM) antibodies was also evaluated by indirect immunofluorescence using commercial kits.

All patients underwent percutaneous liver biopsy with a Menghini needle in accordance with the procedures and precautions previously described.13 Liver histological evaluation was performed according to Desmet and colleagues.14 Serological screening for CD was performed in all patients by serum EmA and anti-tTG assays based on tTG from guinea pig as the antigen, in accordance with the methods described below. Subjects with positive serum EmA and/or anti-tTG were asked to undergo intestinal biopsy and commence a gluten free diet to confirm the suspected CD diagnosis. In the second part of the study we re-evaluated all sera for anti-tTG antibodies with a new ELISA based on human recombinant tTG (h-tTG) as antigen, according to the methods described below.

Control sera for evaluation of anti-tTG antibodies were obtained from two different groups: the first group included 20 EmA positive coeliac patients on a gluten containing diet with total or subtotal intestinal villous atrophy, diagnosed according to the criteria of the European Society of Pediatric Gastroenterology and Nutrition;15 the second group of control sera was obtained from 35 EmA negative healthy subjects who were members of the medical and laboratory personnel of our clinic. Subjects in these control groups were sex and age matched with the hypertransaminasemic patients.

All subjects gave informed consent and the protocol was approved by the ethics committee of our hospital.

SERUM ANTENDOMYSIAL ANTIBODY DETERMINATION
As previously described,16 IgA class EmA values were determined using a commercially available indirect immunofluorescence technique (Anti-endomisio; Eurospital Pharma, Trieste, Italy).

SERUM ANTI-TTG ELISA DETERMINATION USING tTG FROM GUINEA PIG AS ANTIGEN
This assay was performed by an inhouse ELISA in accordance with the method described by Troncone and colleagues,17 adding 5 mmol/l CaCl2 to U bottomed microtitre plates according to Sulkanen and colleagues.8 Values were expressed as a percentage of positive reference sera, obtained from untreated coeliac patients diagnosed according to the criteria of the European Society of Pediatric Gastroenterology and Nutrition,15 showing in all cases the presence of EmA. Anti-tTG values greater than the 95th percentile of the control group, including over 100 healthy controls negative for serum EmA, were considered positive (8% of the reference serum). The intra-assay coefficient of variation for the IgA t-TG autoantibody ELISA was 8.7% (n=22), and the inter-assay coefficient of variation was 10.3% (n=18).

HUMAN RECOMBINANT TRANSGLUTAMINASE
The h-tTG gene was amplified from the intestinal biopsy of a untreated patient with CD using primers specific for the coding region of the gene, as previously described.17 Briefly, cDNA was cloned into an expression vector (pET28b; Novagen, Madison, Wisconsin, USA) expressed in bacteria and purified under non-denaturing conditions using IMAC (Qia-gen, Valencia, California, USA). Purity of the recombinant protein was assessed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis.

SERUM ANTI-tTG ELISA DETERMINATION USING HUMAN RECOMBINANT tTG AS ANTIGEN
This assay was performed in the laboratory of the paediatric department of the University Hospital of Trieste, on serum samples which had been kept frozen at ~80°C; a control test
performed in that laboratory on 20 serum samples in which anti-tTG antibodies were first assayed on fresh serum and then eight months later after freezing at −80°C showed that the preservation did not significantly alter the results (interassay coefficient of variation was 9.6%).

Serum IgA anti-h-tTG antibodies were determined as recently reported, with slight modifications. The human recombinant antigen was diluted in phosphate buffered saline (PBS) to yield a protein concentration of 10 µg/ml. A 0.1 ml aliquot of this solution was placed in each well of a flat bottomed plate (EIA/RIA 2580; Costar, Cambridge, Massachusetts, USA). After an overnight incubation at 4°C, the plates were washed three times in PBS-0.05% Tween 20 and blocked with PBS-0.1% Tween 20 for 20 minutes at room temperature. Serum samples diluted 1:100 in PBS-0.1% Tween 20 were incubated for one hour at room temperature. The plates were washed and incubated for one hour at room temperature with 1:4000 phosphatase conjugated antimouse IgA (Sigma A-3062) diluted in PBS-1% bovine serum albumin-4% polyethylene glycol. The immune reaction was developed by adding substrate solution and absorbance was read in a microplate reader at 405 nm until the positive control serum reached an optical density value of 1.9. Results were expressed as a percentage of the positive control serum. Normal values were taken as <16% which represented a value >2 SD above the mean of 500 healthy subjects. The intra-assay coefficient of variation for the IgA anti-h-tTG autoantibody ELISA was 4% (n=10) and the inter-assay coefficient of variation was 9% (n=10). This ELISA method has a sensitivity of 97% and a specificity of 99%.

INTESTINAL HISTOLOGY

Biopsy specimens were obtained and oriented as previously described. Specimens were embedded in paraffin. Slides were stained with haematoxylin and eosin and graded by conventional histology as normal, partial villous atrophy, and subtotal villous atrophy. Furthermore, a count of the intraepithelial lymphocyte (IEL) population was performed and their number was calculated per number of enterocytes (normal values <35 IEL per 100 enterocytes). Histology was described by an examiner unaware of the laboratory test results.

Table 1  Liver histology findings and viral hepatitis markers in the 98 consecutive hypertransaminasaemia patients included in the study

<table>
<thead>
<tr>
<th>Histology</th>
<th>Anti-HCV+ HBSAg−</th>
<th>Anti-HCV− HBSAg+</th>
<th>Anti-HCV+ HBSAg+</th>
<th>Anti-HCV− HBSAg−</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal histology</td>
<td>1</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Steatosis</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Minimal changes</td>
<td>3</td>
<td>2</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Minimal chronic hepatitis</td>
<td>15</td>
<td>5</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Mild chronic hepatitis</td>
<td>30</td>
<td>—</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Moderate chronic hepatitis</td>
<td>9</td>
<td>2</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Severe chronic hepatitis</td>
<td>3</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Hepatitis with severe fibrosis</td>
<td>13</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td>15</td>
<td>5</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen.

Figure 1  Serum IgA class tissue transglutaminase antibody (anti-tTG) titres determined by ELISA performed using Sigma tTG from guinea pig as the antigen. The results are expressed as AU values. The following groups were studied: group 1, hypertransaminasaemia patients (n=98); group 2, coeliac disease patients (EmA positive) on a gluten containing diet (n=20); group 3, healthy control subjects (EmA negative) (n=35). An arbitrary cut off level for positivity (broken line) was drawn at an AU of 8.

STATISTICAL ANALYSIS

The percentage of anti-tTG and EmA positive results was calculated. Analysis of frequency was performed using the χ² test. Spearman’s r correlation coefficient was used to evaluate the association of serum anti-tTG results with liver histology or laboratory test results. Multiple linear regression analysis was performed to evaluate the association between anti-tTG positivity and serum ALT and AST, serum albumin, serum bilirubin and alkaline phosphatase, serum gamma globulin, serum γ glutamyl transferase, and the presence of autoantibodies (ANA, ASMA, AMA, anti-LKM1) in chronic liver disease patients.

Results

Table 1 summarises the liver histology findings and viral hepatitis marker results in all patients studied.

Regarding serological screening for CD, fig 1 shows anti-tTG values obtained with the ELISA based on tTG from guinea pig as the antigen in subjects with chronic liver disease compared with the two control groups; all CD patients with known EmA positivity (CD controls, group 2) had anti-tTG values above the normal limit (range 10–40 AU) whereas all healthy EmA negative controls (group 3) had values within the normal range. In the hypertransaminasaemic patients (group 1), we found 15/98 (16%) subjects with anti-tTG values above normal; these values were in the same range as those observed in the CD patients. However, when IgA EmA were assayed, only 2/98 (2%) patients with chronic liver disease were positive; in fact, EmA was negative in all anti-tTG negative hypertransaminasaemic patients but also in 13/15 patients positive for serum IgA anti-tTG.

Nine of 15 hypertransaminasaemic patients positive for anti-tTG, including two EmA positive patients, consented to intestinal biopsy for histological study. Intestinal histology showed subtotal mucosa atrophy in two patients who were positive for both EmA and anti-tTG.
Table 2 Clinical, laboratory, and histological characteristics of the 15 subjects positive for serum IgA anti-tTG antibodies, compared with all other anti-tTG negative hypertransaminasaemic patients

<table>
<thead>
<tr>
<th>Case No</th>
<th>Anti-tTG (AU)</th>
<th>EmA</th>
<th>Natural autoantibodies</th>
<th>ALT/AST (U/L)</th>
<th>Liver histology</th>
<th>Intest histology (villi/crypts)</th>
<th>Intestinal histology (IEL)</th>
<th>Associated diseases</th>
<th>Viral markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>17</td>
<td>+</td>
<td>ANA+</td>
<td>40/46</td>
<td>MILH</td>
<td>1.8</td>
<td>63</td>
<td>IIDDm</td>
<td>HCV+</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>-</td>
<td>ASMA+</td>
<td>69/84</td>
<td>S</td>
<td>1.1</td>
<td>73</td>
<td>IIDDm</td>
<td>HCV+</td>
</tr>
<tr>
<td>3</td>
<td>14</td>
<td>+</td>
<td>ASMA+</td>
<td>39/98</td>
<td>MH</td>
<td>3.3</td>
<td>14</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>4</td>
<td>10.5</td>
<td>-</td>
<td>ANA+</td>
<td>177/221</td>
<td>SF</td>
<td>3.4</td>
<td>19</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>5</td>
<td>8.7</td>
<td>-</td>
<td>LKM1+</td>
<td>67/75</td>
<td>MODH</td>
<td>4.0</td>
<td>30</td>
<td>HBV+</td>
<td>—</td>
</tr>
<tr>
<td>6</td>
<td>11</td>
<td>-</td>
<td>None</td>
<td>924/908</td>
<td>SF</td>
<td>2.9</td>
<td>27</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>7</td>
<td>9.4</td>
<td>-</td>
<td>None</td>
<td>84/80</td>
<td>MH</td>
<td>3.6</td>
<td>31</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>8</td>
<td>13</td>
<td>-</td>
<td>ANA+</td>
<td>16/117</td>
<td>LG</td>
<td>3.5</td>
<td>28</td>
<td>CG</td>
<td>HCV+</td>
</tr>
<tr>
<td>9</td>
<td>15</td>
<td>-</td>
<td>None</td>
<td>47/49</td>
<td>MH</td>
<td>Not perf.</td>
<td>—</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>10</td>
<td>15</td>
<td>-</td>
<td>AMA+ LKM1+</td>
<td>31/53</td>
<td>MH</td>
<td>Not perf.</td>
<td>—</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>11</td>
<td>8.4</td>
<td>-</td>
<td>ANA+</td>
<td>116/162</td>
<td>MH</td>
<td>Not perf.</td>
<td>—</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>12</td>
<td>9.7</td>
<td>-</td>
<td>ASMA+ ANA+</td>
<td>121/170</td>
<td>SF</td>
<td>Not perf.</td>
<td>—</td>
<td>Thyroiditis</td>
<td>HCV+</td>
</tr>
<tr>
<td>13</td>
<td>8.8</td>
<td>-</td>
<td>ANA+ AMA+</td>
<td>89/95</td>
<td>MH</td>
<td>Not perf.</td>
<td>—</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>14</td>
<td>16</td>
<td>-</td>
<td>None</td>
<td>42/44</td>
<td>S</td>
<td>2.9</td>
<td>17</td>
<td>—</td>
<td>HCV+</td>
</tr>
<tr>
<td>15</td>
<td>9.9</td>
<td>-</td>
<td>ANA+</td>
<td>84/106</td>
<td>S</td>
<td>Not perf.</td>
<td>—</td>
<td>—</td>
<td>HCV+</td>
</tr>
</tbody>
</table>

**Anti-tTG negative controls**

Range 2-7.2 (villi/crypts) <35/100 enterocytes.

EmA, antiendomysial antibody; tTG, tissue transglutaminase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HCV, hepatitis C virus; HBV, hepatitis B virus; ANA, antinuclear antibodies; AMA, antimitochondrial antibodies; ASMA, antismooth muscle antibodies; LKM, anti-liver-kidney microsomal antibodies; IEL, intraepithelial lymphocytes.

Liver histology: N, normal; S, steatosis; MCHS, minimal changes; MH, minimal chronic hepatitis; MILH, mild chronic hepatitis; MODH, moderate chronic hepatitis; SH, severe chronic hepatitis; SF, hepatitis with severe fibrosis; LC, liver cirrhosis.

Associated diseases: CG, congestive gastropathy; IDDM, insulin dependent diabetes mellitus; NIDDM, non-insulin dependent diabetes mellitus; PU, peptic ulcer; CVD, cardiovascular disease.

Normal reference values: anti-t-TG <8 AU; EmA: serum dilution <1:5; natural autoantibodies: serum dilution <1:80; ALT and AST <40 UI/l; villi/crypts ratio >2.8; CVD, cardiovascular disease.

There was no correlation between anti-tTG positivity and the other independent variables examined (r² = 0.46). Eight months after the conclusion of the first part of the study, we performed an ELISA for IgA anti-tTG antibodies using h-tTG as the antigen, and the sera of all patients included in this study were re-evaluated. In the patient group with chronic liver disease, only the two subjects with atrophy of the intestinal mucosa and serum EmA+ at the moment of diagnosis had elevated anti-tTG antibodies: their values were in the range of those observed in patients with CD (19% and 32.1%, respectively). All other patients with chronic liver disease had anti-tTG values within the normal limit (range 1–13.1 %), including the 13 subjects with false positive anti-tTG values when evaluated with the ELISA based on tTG from guinea pig as the antigen. Finally, in the serum of these 13 patients we repeated the anti-tTG ELISA based on tTG from guinea pig as the antigen.
in all cases a false positive result was confirmed. For the control groups, all CD patients with known EmA+ were positive for serum IgA anti-tTG (range 17–116%) whereas none of the healthy controls were positive (range 1–12.3%).

The two patients with subtotal intestinal mucosa atrophy began a gluten free diet and after 4–5 months of this diet showed negative serum IgA EmA and anti-tTG; in one of these patients, who was anti-HCV positive, hypertransaminasaemia persisted on a gluten free diet. In the other patient, negative for viral hepatitis markers, hypertransaminasaemia disappeared after three months on a gluten free diet. None of the patients positive for anti-tTG but EmA– commenced a gluten free diet.

**Discussion**

It is known that CD can cause chronic hypertransaminasaemia both in adults and in children and the relative risk for CD in human tissues as substrate, and it is not easy to subjectively, it requires monkey oesophagus or rat liver matrix, probably common (or cross reacting) to humans and other mammals. In fact, in the second part of the study when we were able to test our sera for anti-tTG using a pure human recombiant tTG, we did not observe any false positive results: all 13 subjects with false positive anti-tTG values when evaluated with the ELISA based on tTG from guinea pig as antigen resulted in negative values with the new ELISA system. This confirms that human tTG ELISA has a higher diagnostic accuracy in CD diagnosis than the commonly used anti-tTG ELISA based on guinea pig antigen. However, it must be remembered that all gastroenterological studies published to date which reported a very high specificity of anti-tTG determination for CD diagnosis were performed with the same ELISA used in the first part of the present study (based on tTG from guinea pig liver) and that this method has been suggested for large scale CD screening. Our findings appear to be linked to the presence of chronic liver disease and/or hyperglobulinaemia and we emphasise that such a high frequency of false positive anti-tTG results cannot be extrapolated to the general population.

In conclusion, we found a high frequency of false positive anti-tTG test results in patients with chronic liver disease using the commonly used anti-tTG ELISA based on tTG from guinea pig liver as antigen. The presence of anti-tTG did not correlate with the presence of EmA or CD. We demonstrated that these false positive results were due to the “nature” of the antigen used in the ELISA system and that the ELISA based on human recombiant tTG as antigen, was employed. Thus the anti-human-tTG ELISA, and not the anti-tTG assay based on tTG from guinea pig as the antigen, must be used as a screening tool for CD in patients with chronic liver disease.

This work was supported by a grant to G Montalto, 60% from MURST, and by grant 12/99 from IRCCS “Burlo Garofolo”.


Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease
A Carroccio, L Giannitrapani, M Soresi, T Not, G Iacono, C Di Rosa, E Panfili, A Notarbartolo and G Montalto
Gut 2001 49: 506-511
doi: 10.1136/gut.49.4.506